| Original language | English (US) |
|---|---|
| Pages (from-to) | 1648-1652 |
| Number of pages | 5 |
| Journal | Clinical and Experimental Allergy |
| Volume | 51 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2021 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical and Experimental Allergy, Vol. 51, No. 12, 12.2021, p. 1648-1652.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab
AU - Al-Shaikhly, Taha
AU - MacDonald, James W.
AU - Bammler, Theo K.
AU - Altman, Matthew C.
AU - Ayars, Andrew G.
AU - Petroni, Daniel H.
AU - Tilles, Stephen A.
AU - Henderson, William R.
N1 - Funding Information: T.A.‐S. has patents MicroRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria and Methods of Treatment using Omalizumab and Ligelizumab pending. J.W.M. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; In addition, J.W.M. has patents MicroRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria and Methods of Treatment using Omalizumab and Ligelizumab pending. T.K.B. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; In addition, T.K.B. has patents MicroRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria and Methods of Treatment using Omalizumab and Ligelizumab pending. M.C.A. reports personal fees from Regeneron, outside the submitted work. A.G.A. has nothing to disclose. D.H.P. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; grants from Genentech, DBV Technologies, Aimmune, Regeneron, and NIH/NIAID (Immune Tolerance Network), outside the submitted work. S.A.T. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; grants from Genentech, DBV Technologies, Aimmune, Regeneron, NIH/NIAID (Immune Tolerance Network), and personal fees from Aimmune, outside the submitted work. W.R.H. reports grant from Novartis Pharmaceuticals Corporation, during the conduct of the study; In addition, W.R.H. has patents MicroRNAs as Predictors of Response to Anti‐IgE Therapies in Chronic Spontaneous Urticaria and Methods of Treatment using Omalizumab and Ligelizumab pending. Funding Information: Funding for this investigator‐initiated study was provided by Novartis Pharmaceuticals Corporation (grant number CIGE025EUS44T to W.R.H.).
PY - 2021/12
Y1 - 2021/12
UR - http://www.scopus.com/inward/record.url?scp=85115104375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115104375&partnerID=8YFLogxK
U2 - 10.1111/cea.14014
DO - 10.1111/cea.14014
M3 - Letter
C2 - 34519110
AN - SCOPUS:85115104375
SN - 0954-7894
VL - 51
SP - 1648
EP - 1652
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 12
ER -